Assessment of mumps-containing vaccine effectiveness by dose during 2006 to 2020 in Quzhou, China.
Hum Vaccin Immunother
; 18(5): 2086774, 2022 11 30.
Article
em En
| MEDLINE
| ID: mdl-35675040
Mumps cases were reported frequently when a routine dose measles-mumps-rubella(MMR) achieved high coverage in Quzhou. The supplementary immunization activities (SIA) using measles mumps (MM) was conducted to control mumps outbreaks. The effectiveness of one and two doses of mumps-containing vaccine (MuCV) was assessed using surveillance data in this study. Mumps cases and immunization information were retrieved from the National Notifiable Disease Reporting System (NNDRS) and the Zhejiang Provincial Immunization Information System (ZJIIS), respectively. Mumps cases of children born from 2006 to 2010 were included. Vaccine effectiveness by dose was calculated using the screening method. A total of 956 mumps cases were identified, of whom 754 (78.9%) had received one dose of MuCV; 108 (11.3%) had received two doses; 94 (9.8%) were unvaccinated. The coverage of one-dose MuCV in the 2006-2010 birth cohorts ranged from 91.6% to 98.9%. Except the 2009 birth cohort in which the coverage of two doses of MuCV was 55.1%, the others were less than 10%. Vaccine effectiveness (VE) of one dose ranged from 47.4% to 86.0%, while VE of two doses ranged from 64.0% to 92.4%. The VE of one and two doses of MuCV waned over time, but the VE of two doses was consistently higher than that of one dose in the same period. The vaccine schedule with two-dose MMR should be implemented among children in Quzhou. The optimal age for the second dose needs to be further evaluated.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Rubéola (Sarampo Alemão)
/
Sarampo
/
Caxumba
Limite:
Child
/
Humans
/
Infant
País como assunto:
Asia
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article